



ASX ANNOUNCEMENT
15 September 2020

Clinical Program Updates

Bionomics Limited (ASX:BNO, OTCQB:BNOEF), a global, clinical stage biopharmaceutical company, provided updates on the development of BNC210 which has been granted Fast Track Designation by the US Food and Drug Administration for the treatment of post-traumatic stress disorder (PTSD) and other trauma-related and stress-related disorders and on the ongoing collaboration with MSD (a tradename of Merck & Co., Inc., Kenilworth NJ USA) for the treatment of cognitive deficits in Alzheimer's and other disorders.

- **BNC210 Update:**
 - **The spray dried tablet formulation has been optimized to increase the amount of BNC210 in each tablet and manufacturing of the optimized tablets is underway in preparation of the start of a multiple dosing pharmacokinetic trial in healthy volunteers scheduled for late Dec 2020/ early Jan 2021**
 - **Large scale GMP manufacture of BNC210 drug substance and tablets for the Phase 2b PTSD trial projected for mid 2021 has been contracted**
- **MSD Collaboration Update:**
 - **Phase 1 safety clinical trials of the lead molecule in healthy subjects have been completed and there are ongoing plans for further biomarker studies**
 - **A backup molecule that showed an improved potency profile in preclinical animal models versus the current lead molecule is advancing into Phase 1 clinical trials**

Dr. Errol De Souza, Executive Chairman of Bionomics said "We are pleased with the progress made in optimizing the BNC210 tablet formulation based on both *in vitro* studies and evaluation in pharmacokinetic studies in dogs. We continue on our previously communicated timelines and confirming the pharmacokinetic profile of the optimized BNC210 tablet in the multi dose study in healthy subjects is projected for the end of the year, while we prepare for the start of the Phase 2b PTSD study in mid 2021. Furthermore, we are excited to report progress in our collaboration with MSD."

AUTHORISED BY THE EXECUTIVE CHAIRMAN, DR ERROL DE SOUZA

FOR FURTHER INFORMATION PLEASE CONTACT:

Mr Jack Moschakis
Legal Counsel & Company Secretary
Bionomics Limited
31 Dalglish St,
Thebarton, South Australia
+61 8 8354 6100
jmoschakis@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO, OTCQB:BNOEF) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in development for initiation of a second Phase 2 trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with MSD.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210), its licensing agreements with MSD and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.